T1 efficacy of EVP-ABD: A potential manganese-based MR contrast agent for hepatic vascular and tissue phase imaging

Journal of Magnetic Resonance Imaging

Volumn 16, Issue 6, 2002, Pages 668-675

  Zuo, C S ^a   Seoane, P ^b   Lanigan, T ^a   Harnish, P ^b   Prasad, P V ^c   Storey, P ^c   Li, W ^c   Rofsky, N M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Eagle Vision Pharmaceutical Corporation   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

EVP ABD; Hepatic; Intracellular; Manganese; MRI contrast agent; Vascular

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; MANGAFODIPIR;

ANIMAL TISSUE; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; IMAGE ANALYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIGNAL NOISE RATIO; SWINE;

ANIMALS; AORTA; CONTRAST MEDIA; EDETIC ACID; GADOLINIUM DTPA; LIVER; MAGNETIC RESONANCE IMAGING; MANGANESE; PYRIDOXAL PHOSPHATE; SWINE;

EID: 0036890798     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.10203     Document Type: Article

References (37)

1. Schuhmann-Giampieri G. Liver contrast media for magnetic resonance imaging: Interrelations between pharmacokinetics and imaging. Invest Radiol 1993;28:753-761.
2. Mitchell DG. Liver I: Currently available gadolinium chelates. Magn Reson Imaging Clin N Am 1996;4:37-51.
3. Rofsky NM, Weinreb J, Bernardino M, et al. Hepatocellular tumors: Characterization with Mn-DPDP-enhanced MR imaging. Radiology 1993;188:53-59.
4. Bartolozzi C, Donati F, Cioni D, et al. MnDPDP-enhanced MRI vs. dual-phase spiral CT in the detection of hepatocellular carcinoma in cirrhosis. Eur Radiol 2000;10:1697-1702.
5. Rofsky NM, Earls JP. Mangafodipir trisodium injection (MriDPDP). Magn Reson Imaging Clin N Am 1996;4:73-85.
6. Wang C. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas. Acta Radiol Suppl 1998;415:1-31.
7. Wang C, Gordon P, Hustvedt S, et al. MR imaging properties and pharmacokinetics of MnDPDP in healthy volunteers. Acta Radiol 1997;38:665-676.
8. Toft K, Hustvedt S, Grant D, et al. Metabolism and pharmacokinetics of MnDPDP in man. Acta Radiol 1997;38:677-689.
9. Vogl T, Hamm B, Schnell B. et al. Mn-DPDP enhancement patterns of hepatocellular lesions on MR images. J Magn Reson Imaging 1993;3:51-58.
10. Southon T, Grant D, Bjornerud A, et al. NMR relaxation studies with MnDPDP. Acta Radiol 1997;38:708-716.
11. Murakami T, Baron R, Peterson M. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP). Radiology 1996;200:69-77.
12. Elizondo G, Fretz C, Stark D, et al. Preclinical evaluation of MnDPDP: New paramagnetic hepatobiliary contrast agent for MR imaging. Radiology 1991;178:73-78.
13. Martin DR, Semelka RC, Chung J-J, Balci NC, Wilber K. Sequential use of gadolinium chelate and mangafodipir trisodium for the assessment of focal liver lesions: Initial observations. Magn Reson Imaging 2000;18:955-963.
14. Sahani D, Prasad S, Stein J, et al. Dual contrast liver MRI imaging for lesion detection and characterization. In: Proceedings of the 87th Scientific Assembly and Annual Meeting. Radiological Society of North America, Chicago, IL. 2001. p 650, abstract 0105Gl-e.
15. Kang Y, Gore J, Armitage I. Studies of factors affecting the design of NMR contrast agents: Manganese in blood as a model system. Magn Reson Med 1984;1:396-409.
16. Koenig S, Baglin C, Brown III R. Magnetic field dependence of solvent proton relaxation induced by Gd3+ and Mn2+ complexes. Magn Reson Med 1984;1:496-501.
17. Koenig S, Brown III R. Magnetic field dependence of proton relaxation rates in tissue with added Mn2+: Rabbit liver and kidney. Magn Reson Med 1985;2:159-168.
18. Mendonca-Dias M, Gaggelli E, Lauterbur P. Paramagnetic contrast agents in nuclear magnetic resonance medical imaging. Semin Nucl Med 1983;13:364-376.
19. Koenig S, Brown III R. Relaxation of solvent protons by paramagnetic ions and its dependence on magnetic field and chemical environment: Implications for NMR imaging. Magn Reson Med 1984;1:478-495.
20. Kang Y, Gore J. Studies of tissue NMR relaxation enhancement by manganese. Invest Radiol 1984;19:399-407.
21. Harnish P, Seoane P, Vessey A. Manganese compositions and methods for MRI. United States Patent 5,980.863. 1999.
22. Storey P, Li W, Seoane P, et al. Preliminary evaluation of EVP-ABD as a liver contrast agent exhibiting both a vascular and a tissue phase. In: Proceedings of the 9th Annual Meeting of ISMRM. Glasgow, Scotland, 2001. p 704.
23. Borg D, Cotzias G. Manganese metabolism in man: Rapid exchange of Mn56 with tissue as demonstrated by blood clearance and liver uptake. J Clin Invest 1958;37:1269-1278.
24. Atkins H, Som P, Fairchild R, Hui J, Schachner E, Goldman A, Ku T. Myocardial positron tomography with Manganese-52m. Radiology 1979;133:769-774.
25. Slichter C. Principles of Magnetic Resonance. New York: Springer-Verlag: 1989.
26. Rofsky NM, Lee VS, Laub G, et al. Abdominal MR imaging with a volumetric interpolated breath-hold examination. Radiology 1999;212:876-884.
27. Lee VS, Rofsky NM, Morgan G, et al. Technical innovation: Volumetric mangafodipir trisodium-enhanced cholangiography to define intrahepatic biliary anatomy. AJR Am J Roentgenol 2001;176:906-908.
28. Colet J, Vander Elst L, Muller R. Dynamic evaluation of the hepatic uptake and clearance of manganese based MRI contrast agents: A 31P NMR study on the isolated and perfused rat liver. J Magn Reson Imaging 1998;8:663-669.
29. Hustvedt S, Grant D, Southon T, et al. Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration. Acta Radiol 1997;38:690-699.
30. Ni Y, Petre C, Bosmans H, Miao Y, Grant D, Baert A, Marchal G. Comparison of manganese biodistribution and MR contrast enhancement in rats after intravenous injection of MnDPDP and MnCl2. Acta Radiol 1997;38:700-707.
31. Manfredi R, Maresca G, Baron R, et al. Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging 1999;9:704-710.
32. Gehl H, Bourne M, Grazioli L, Moller A, Lodemann K. Off-site evaluation of liver lesion detection by Gd-BOPTA-enhanced MR imaging. Eur Radiol 2001;11:187-192.
33. Giovagnoni A, Paci E. Liver III: gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Magn Reson Imaging Clin N Am 1996;4:61-72.
34. Marchal G, Zhang X, Ni Y, et al. Comparison between Gd-DTPA, Gd-EOB-DTPA, and Mn-DPDP in induced HCC in rats: A correlation study of MR imaging, microangiography, and histology. Magn Reson Imaging 1993;11:665-674.
35. Reimer P, Rummeny E, Daldrup H, et al. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: Preliminary results with dynamic MR imaging. Eur Radiol 1997;7:275-280.
36. Stern W, Schick F, Kopp A, et al. Dynamic MR imaging of liver metastases with Gd-EOB-DTPA. Acta Radiol 2000;41:255-262.
37. Vogl T, Kummel S, Hammerstingl R, et al. Liver tumors: Comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996;200:59-67.